Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fexuprazan-based triple therapy vs PPI-based triple therapy for Helicobacter pylori eradication
KCT0008525Phase 4Completed
- Sponsor
- Daewoong Pharmaceutical
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of fexuprazan in Helicobacter pylori infection, gastric cancer (GC), gastric ulcer, Gastric Marginal Zone B-Cell Lymphoma Of Mucosa-Associated Lymphoid Tissue, gastritis, sponsored by Daewoong Pharmaceutical. Started Apr 2023; status: completed.
02
Drugs
fexuprazan
03
Conditions
Helicobacter pylori infectiongastric cancer (GC)gastric ulcerGastric Marginal Zone B-Cell Lymphoma Of Mucosa-Associated Lymphoid Tissuegastritis
Beyond the preview
Go deeper on KCT0008525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0008525.